# Safety, Immunogenicity Study of GSK Biologicals' Pandemic Influenza Candidate Vaccine (H1N1) (GSK2340272A)

> **NCT00971321** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 157 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** Pandemic influenza vaccine GSK2340272A

## Key facts

- **NCT ID:** NCT00971321
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-09-10
- **Primary completion:** 2010-11-24
- **Final completion:** 2010-11-24
- **Target enrollment:** 157 (ACTUAL)
- **Last updated:** 2019-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00971321

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00971321, "Safety, Immunogenicity Study of GSK Biologicals' Pandemic Influenza Candidate Vaccine (H1N1) (GSK2340272A)". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00971321. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*